{"id":"NCT00733902","sponsor":"Pfizer","briefTitle":"Tanezumab in Osteoarthritis of the Knee","officialTitle":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09-15","primaryCompletion":"2009-08-24","completion":"2010-01-14","firstPosted":"2008-08-13","resultsPosted":"2021-03-22","lastUpdate":"2021-03-22"},"enrollment":697,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis","Osteoarthritis"],"interventions":[{"type":"BIOLOGICAL","name":"tanezumab","otherNames":[]},{"type":"BIOLOGICAL","name":"tanezumab","otherNames":[]},{"type":"BIOLOGICAL","name":"tanezumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tanezumab 10 mg","type":"EXPERIMENTAL"},{"label":"Tanezumab 5 mg","type":"EXPERIMENTAL"},{"label":"Tanezumab 2.5 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Test the efficacy and safety of 3 doses in Osteoarthritis of the knee in patients.","primaryOutcome":{"measure":"Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF)","timeFrame":"Baseline (Day 1), Week 16","effectByArm":[{"arm":"Placebo","deltaMin":7.05,"sd":1.45},{"arm":"Tanezumab 2.5 mg","deltaMin":7.16,"sd":1.44},{"arm":"Tanezumab 5 mg","deltaMin":7.19,"sd":1.41},{"arm":"Tanezumab 10 mg","deltaMin":6.99,"sd":1.43}],"pValues":[{"comp":"OG000 vs OG001","p":"0.015"},{"comp":"OG000 vs OG002","p":"0.005"},{"comp":"OG000 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":3},"locations":{"siteCount":82,"countries":["United States"]},"refs":{"pmids":["37460782","30936738","26554876"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091011&StudyName=Tanezumab%20in%20Osteoarthritis%20of%20the%20Knee%20"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":172},"commonTop":["Headache","Upper respiratory tract infection","Arthralgia","Paraesthesia","Oedema peripheral"]}}